Jung Wook Kang
Research Subjects
Jung Wook Kang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Trageser
Oncology R&D, Pfizer Worldwide Research, San Diego, California
23 shared publications - Amy Jackson-Fisher
10Translational Oncology, Pfizer Inc., San Diego, California
23 shared publications - Anand Giddabasappa
Animal Models and Imaging, Comparative Medicine-Drug Safety R&D, Pfizer Inc, United States
23 shared publications - Andrea T. Hooper
14 Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA
23 shared publications - Ashley Thomas
Oncology R&D, Pfizer Worldwide Research, San Diego, California
23 shared publications - Bernard S. Buetow
Pfizer Inc., San Diego, California, USA
23 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-CRX-11201 in vivo model %TGI vs. vehicle at D7
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-CRX-11201 in vivo model %TGI vs. vehicle at D7
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
HCC-1954 in vivo model %TGI vs. vehicle at D16
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
HCC-1954 in vivo model %TGI vs. vehicle at D16
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MDA-MB-468 in vivo model %TGI vs. vehicle at D19
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MDA-MB-468 in vivo model %TGI vs. vehicle at D19
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression quantification in human breast cancer cell lines by flow cytometry
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression quantification in human breast cancer cell lines by flow cytometry
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-BRX-26305 in vivo model %TGI vs. vehicle at D17
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-BRX-26305 in vivo model %TGI vs. vehicle at D17
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
E0771-hB7-H4 /hCD3e in vivo model %TGI vs. vehicle at D42
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
E0771-hB7-H4 /hCD3e in vivo model %TGI vs. vehicle at D42
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
EC50 of PF-07260437 in inducing redirected T cell killing in vitro in cell lines expressing various levels of B7-H4
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
EC50 of PF-07260437 in inducing redirected T cell killing in vitro in cell lines expressing various levels of B7-H4
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MX-1-luc in vivo model %TGI vs. vehicle at D24
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
MX-1-luc in vivo model %TGI vs. vehicle at D24
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression as a percentage of cells with a particular H-Score
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
B7-H4 expression as a percentage of cells with a particular H-Score
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-BRX-24301 in vivo model %TGI vs. vehicle at D21
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies
PDX-BRX-24301 in vivo model %TGI vs. vehicle at D21